9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

DENdritic Cell Immunotherapy for Mesothelioma

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > DENdritic Cell Immunotherapy for Mesothelioma

DENdritic Cell Immunotherapy for Mesothelioma

Estimated reading time: < 1 min

Condition: Mesothelioma

Estimated Enrollment: 230

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Recruiting

Study Results: No Results Available

Outcome Measures: Overall survival rate,  ,  ,

Interventions: MesoPher,

Phase:

Study Type: Interventional

Study Design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label),Primary Purpose: Treatment

Primary Completion Date: January 15, 2021

Completion Date: January 15, 2021

Last  Posted Date: August 1, 2018

Location: University Hospital Antwerp, Antwerp, Belgium

Website Link: https://ClinicalTrials.gov/show/NCT03610360

Was this article helpful?
Dislike 0